The study, realized by a team of nine researchers and led by Cemcat and VHIR, brings encouraging results for multiple sclerosis and autoimmune disorders treatment with DNA vaccines. The aim of the research was to identify the mechanisms of DNA vaccines that cause an immunological regulation in the animal model of multiple sclerosis and consequently, to investigate the therapeutic effects that could have in the inflammation and the degenerative changes of patients. Researchers have analyzed the effect of DNA vaccines in the tissue of the central nervous system of mice. The animals were divided in four groups and were vaccinated twice in a fortnight, with different types of DNA which contained the gens for the production of different myelin proteins. The results of the study, "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464883/" published in Journal Neuroinflammation, determine that the vaccine with the myelin glycoprotein of the oligodendrocytes (MOG-ADN) reduces the clinical symptoms and the hurt in the brain tissue associated to the disease in the animal model of multiple sclerosis. Besides, the treatment increased the production of regulatory T cells and raised the expression levels of gens with neuroprotection functions.For the first time, these results suggest that the positive effects of the vaccines with DNA in the animal model of multiple sclerosis are not only limited to anti-inflamatory mechanisms, but also can be effective as neuroprotection mechanisms. Despite the conclusions of the study are only applied to the animal model, the results obtained could determine the security of using DNA vaccines in human studies.